Conference Coverage

Sex differences seen in inflammatory arthritis health care use


 

FROM THE LANCET SUMMIT ON SEX AND GENDER IN RHEUMATOLOGY

Women seek out care, do repeat visits

Several reasons may explain why utilization was higher in females. Women with IA have a higher overall risk of musculoskeletal conditions such as osteoarthritis, which could have driven the health care encounters. Numerous studies have also reported that female patients have a lower threshold for pain as well as a greater tendency to seek out health care.

Additionally, female patients often present with pain and fatigue, which are often misdiagnosed as fibromyalgia or depression. Therefore, they often require repeated health care encounters to arrive at an IA diagnosis, Ms. Tarannum said.

An early prodromal phase in females could have triggered a health care encounter as well.

Men, by comparison, are more likely to have acute-onset or severe disease. Objective signs and radiologic features can facilitate diagnosis in men, she said. Male patients also show more reluctance in seeking care, have a higher threshold for pain, and are less likely to have a usual source of care such as a family physician.

Higher confidence in hospital-based emergency services also could have resulted in more ED visits and lower health care use in men. Better response to treatments could also have resulted in fewer episodes of rheumatology care after diagnosis.

The results aren’t surprising, said Scott Zashin, MD, a rheumatologist in Dallas who wasn’t a part of the study.

“At least in terms of musculoskeletal disorders, my clinical experience suggests that women are more compliant with their follow-up than male patients. Especially with gout, a common type of arthritis in men, male patients may wait until their symptoms are severe before seeking medical attention,” Dr. Zashin said.

The Enid Walker Graduate Student Award for Research in Women’s Health provided funding for this study.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Biosimilar-to-biosimilar switches deemed safe and effective, systematic review reveals
MDedge Family Medicine
FDA approves adalimumab-bwwd biosimilar (Hadlima) in high-concentration form
MDedge Family Medicine
Olokizumab proves noninferior to adalimumab for RA in phase 3 trial
MDedge Family Medicine
Autoimmune disease patients’ waxing, waning response to COVID vaccination studied in-depth
MDedge Family Medicine
Inhaled, systemic steroids linked to changes in brain structure
MDedge Family Medicine
Possible sex differences found in response to first treatments for early RA
MDedge Family Medicine
Autoimmune diseases linked to spike in post-MI events
MDedge Family Medicine
Trial shows olokizumab’s effect in nonresponders to TNF inhibitors in RA
MDedge Family Medicine
Severe COVID-19–related outcomes found worse in men with RA
MDedge Family Medicine
Hormones’ impact described in transgender rheumatology patients
MDedge Family Medicine